Spero Therapeutics, Inc.
SPRO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3 | $12 | $6 | $15 |
| % Growth | -74.2% | 100.9% | -61% | – |
| Cost of Goods Sold | $0 | $0 | $14 | $95 |
| Gross Profit | $3 | $12 | -$8 | -$80 |
| % Margin | 100% | 100% | -131.6% | -529% |
| R&D Expenses | $9 | $11 | $14 | $29 |
| G&A Expenses | $4 | $6 | $7 | $6 |
| SG&A Expenses | $4 | $6 | $7 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | -$2 | -$2 | -$13 | -$94 |
| Operating Expenses | $11 | $14 | $7 | -$58 |
| Operating Income | -$8 | -$2 | -$15 | -$22 |
| % Margin | -259.7% | -20.7% | -250.8% | -144.4% |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$7 | -$2 | -$14 | -$21 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$2 | -$14 | -$21 |
| % Margin | -242.2% | -14.4% | -236.1% | -138.8% |
| EPS | -0.13 | -0.03 | -0.25 | -0.39 |
| % Growth | -329% | 87.9% | 35.9% | – |
| EPS Diluted | -0.13 | -0.03 | -0.25 | -0.39 |
| Weighted Avg Shares Out | 56 | 56 | 55 | 54 |
| Weighted Avg Shares Out Dil | 56 | 56 | 55 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$2 | -$15 | -$21 |
| % Margin | -242.2% | -20% | -247.8% | -138.6% |